Navigating SG-related Diarrhea

EP: 1.Overview of Current ADCs in Breast Cancer

EP: 2.ADCs in Breast Cancer: Mechanism of Action, and Components

EP: 3.Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

EP: 4.Expert Perspectives on the Management of SG-Related Neutropenia

Now Viewing

EP: 5.Navigating SG-related Diarrhea

EP: 6.Expert Insights: SG Adverse Events Management including Alopecia & Nausea

EP: 7.Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

EP: 8.Clinical Management Considerations: Pneumonitis associated with T-DXd

EP: 9.Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

EP: 10.Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

EP: 11.Future Perspectives on ADCs in Breast Cancer

EP: 12.Expert Insights: Investigational ADCs Safety Profiles

EP: 13.Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

• Please comment on your absolute neutrophil count cutoff for dose reductions and/or delay of sacituzumab govitecan (SG) therapy.
• How do you manage subsequent doses for patients who experienced febrile neutropenia with the previous cycle?
• How often do you see diarrhea (associated with SG) in your clinical practice? How does it compare to the rates reported in clinical trials (ASCENT, TROPiCS-02)?
• Are there risk factors that can predict those who are at higher risk for developing diarrhea?
• Are there any situations where you would consider testing for UGT1A1*28 homozygosity?
• Please comment on how you typically manage SG-related diarrhea.
• Are you utilizing prophylactic atropine or loperamide to prevent cholinergic syndrome prior to Cycle 1 of SG?
• Please comment on your management strategy for SG-related diarrhea (any similarities vs differences).